Mucosal immunization with IpaD adjuvanted by IC31® elicits protection in a murine model of shigellosis

Abstract

Mucosal immunization with the conserved Shigella protein IpaD formulated with the two-component adjuvant IC31® provided protection in the murine lung model. Neither the recombinant IpaD alone nor IC31® with an irrelevant protein antigen was effective. IpaD-specific serum IgG and IgA levels obtained by IC31®-adjuvantation were comparable to those induced by known mucosal adjuvants.